Quarterly report · Q2
7745.TEDINET S100PKQD
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥27.2bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Revenue | ¥51.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥23.9bn | 2021-04-01 → 2021-09-30 | Cons. | Net sales |
| Operating income | ¥1.8bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Operating income | ¥2.1bn | 2021-04-01 → 2021-09-30 | Cons. | Operating income |
| Ordinary income | ¥2.2bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥5.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.2bn | 2021-04-01 → 2021-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥2.2bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥2.2bn | 2021-04-01 → 2021-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥1.5bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.6bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.4bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥1.5bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Net income | ¥1.5bn | 2021-04-01 → 2021-09-30 | Cons. | Profit loss |
| Total assets | ¥66.3bn | at 2022-09-30 | Cons. | Assets |
| Total assets | ¥59.2bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥54.5bn | at 2021-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥34.3bn | at 2022-09-30 | Cons. | Liabilities |
| Total liabilities | ¥32.2bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥32.0bn | at 2022-09-30 | Cons. | Net assets |
| Net assets / equity | ¥27.0bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥24.4bn | at 2021-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥13.5bn | at 2022-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥11.9bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥12.8bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.0bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥11.1bn | at 2021-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥12.1bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.4bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.2bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥626m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.4bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥317m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥741m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.9bn | 2021-04-01 → 2021-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥53.43 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.25 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥172.92 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥66.02 | 2021-04-01 → 2021-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥38.37 | 2021-07-01 → 2021-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥53.38 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥172.66 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥65.91 | 2021-04-01 → 2021-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 48.1% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.8% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.0% | at 2021-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 97
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥13.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥13.9bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥1.8bn |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥3.3bn |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥3.1bn |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥211m |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥370m |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥4.3bn |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-09-30 | −¥29m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.2bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1.7bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥317m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.9bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥245m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥4.7bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥252m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥471m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥470m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥52m |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.0bn |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥4.0bn |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥0 |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥527m |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥9.0bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥7.0bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥1.9bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥76m |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥8.2bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.8bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥5.5bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥845m |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥17.0bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥13.2bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3.8bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥817m |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥21.5bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥11.4bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥10.1bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.6bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥845m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-09-30 | −¥11.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-09-30 | −¥11.4bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-09-30 | −¥979m |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥1.8bn |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥1.7bn |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥115m |
| jpcrp040300-q2r_E02344-000America Measuring Instrumentsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥68m |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥3.5bn |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥3.5bn |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥3m |
| jpcrp040300-q2r_E02344-000America Medical And Health Systemreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥120m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥3.4bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Measuring Instrumentsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥229m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥3.9bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥274m |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥3.6bn |
| jpcrp040300-q2r_E02344-000Asia And Oceania Medical And Health Systemreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥114m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥437m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥437m |
| jpcrp040300-q2r_E02344-000Europe Measuring Instrumentsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥7m |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥3.7bn |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥3.7bn |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥4m |
| jpcrp040300-q2r_E02344-000Europe Medical And Health Systemreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥473m |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥9.0bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥7.4bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥1.5bn |
| jpcrp040300-q2r_E02344-000Japan Measuring Instrumentsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥155m |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥7.5bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥2.7bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥4.8bn |
| jpcrp040300-q2r_E02344-000Japan Medical And Health Systemreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥1.3bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E02344-000Japan Semiconductor Relatedreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥620m |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥14.6bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥11.6bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥3.0bn |
| jpcrp040300-q2r_E02344-000Measuring Instrumentsreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥460m |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥18.5bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥10.1bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | revenue intersegment | 2021-04-01 → 2021-09-30 | ¥8.4bn |
| jpcrp040300-q2r_E02344-000Medical And Health Systemreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥2.0bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | revenue | 2021-04-01 → 2021-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | revenue external | 2021-04-01 → 2021-09-30 | ¥2.1bn |
| jpcrp040300-q2r_E02344-000Semiconductor Related Businessreportable segment | segment profit | 2021-04-01 → 2021-09-30 | ¥620m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 620
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 3060000 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.1104 | |
| Number of shares held | CurrentQuarterInstant_No2MajorShareholdersMember | 1128000 | |
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.0407 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 1017000 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.0367 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 973000 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0351 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 683000 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0247 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 625000 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0225 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 606000 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0219 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 583000 | |
| Shareholding ratio | CurrentQuarterInstant_No8MajorShareholdersMember | 0.0210 | |
| Number of shares held | CurrentQuarterInstant_No9MajorShareholdersMember | 490000 | |
| Shareholding ratio | CurrentQuarterInstant_No9MajorShareholdersMember | 0.0177 | |
| Number of shares held | CurrentQuarterInstant_No10MajorShareholdersMember | 466000 | |
| Shareholding ratio | CurrentQuarterInstant_No10MajorShareholdersMember | 0.0168 | |
| Number of shares held | CurrentQuarterInstant | 9634000 | |
| Shareholding ratio | CurrentQuarterInstant | 0.3475 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 117000 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 27616100 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 276161 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 112108 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 27845208 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 276161 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 117000 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 117000 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.0042 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 117000 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 117000 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.0042 | |
| Cash and deposits | Prior1YearInstant | 11882000000 | JPY |
| Cash and deposits | CurrentQuarterInstant | 13528000000 | JPY |
| Notes and accounts receivable trade and contract assets | Prior1YearInstant | 14114000000 | JPY |
| Notes and accounts receivable trade and contract assets | CurrentQuarterInstant | 14104000000 | JPY |
| Merchandise and finished goods | Prior1YearInstant | 7337000000 | JPY |
| Merchandise and finished goods | CurrentQuarterInstant | 9851000000 | JPY |
| Work in process | Prior1YearInstant | 4019000000 | JPY |
| Work in process | CurrentQuarterInstant | 5071000000 | JPY |
| Raw materials and supplies | Prior1YearInstant | 5225000000 | JPY |
| Raw materials and supplies | CurrentQuarterInstant | 6148000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |